These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

388 related articles for article (PubMed ID: 21677471)

  • 1. Changing pathology with changing drugs: tumors of the gastrointestinal tract.
    Cervera P; Fléjou JF
    Pathobiology; 2011; 78(2):76-89. PubMed ID: 21677471
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting c-kit mutations in solid tumors: scientific rationale and novel therapeutic options.
    Demetri GD
    Semin Oncol; 2001 Oct; 28(5 Suppl 17):19-26. PubMed ID: 11740803
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetics of hepatobiliary carcinogenesis.
    Nault JC; Zucman-Rossi J
    Semin Liver Dis; 2011 May; 31(2):173-87. PubMed ID: 21538283
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monoclonal antibodies in gastrointestinal cancers.
    Bronte G; Cicero G; Cusenza S; Galvano A; Musso E; Rizzo S; Sortino G; Roselli M; Bazan V; Fiorentino E; Russo A
    Expert Opin Biol Ther; 2013 Jun; 13(6):889-900. PubMed ID: 23441760
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of response to targeted therapies for gastrointestinal stromal tumors.
    Marrari A; Wagner AJ; Hornick JL
    Arch Pathol Lab Med; 2012 May; 136(5):483-9. PubMed ID: 22229850
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Involvement of signaling molecules in the prediction of response to imatinib treatment in metastatic GIST patients.
    Valadão M; Braggio D; Santos AF; Pimenta-Inada HK; Linhares E; Gonçalves R; Romano S; Vilhena B; Small I; Cubero D; Cruz F; Oliveira AT; Martinho O; Reis RM; Guimarães DP; Ferreira CG
    J Surg Res; 2012 Nov; 178(1):288-93. PubMed ID: 22516345
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted therapies and predictive markers in epithelial malignancies of the gastrointestinal tract.
    McIntire M; Redston M
    Arch Pathol Lab Med; 2012 May; 136(5):496-503. PubMed ID: 22229849
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic significance of c-erbB-2 gene expression in pancreatic cancer patients.
    Novotný J; Petruzelka L; Vedralová J; Kleibl Z; Matous B; Juda L
    Neoplasma; 2001; 48(3):188-91. PubMed ID: 11583287
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of localized gastrointestinal stromal tumors and adjuvant therapy with imatinib.
    López RL; del Muro XG
    Anticancer Drugs; 2012 Jun; 23 Suppl():S3-6. PubMed ID: 22739667
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Established and Potential Predictive Biomarkers in Gastrointestinal Cancer--c-Kit, Her2, Ras and Beyond.
    Koch C; Trojan J
    Digestion; 2015; 91(4):294-302. PubMed ID: 25924988
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.
    Demetri GD; von Mehren M; Blanke CD; Van den Abbeele AD; Eisenberg B; Roberts PJ; Heinrich MC; Tuveson DA; Singer S; Janicek M; Fletcher JA; Silverman SG; Silberman SL; Capdeville R; Kiese B; Peng B; Dimitrijevic S; Druker BJ; Corless C; Fletcher CD; Joensuu H
    N Engl J Med; 2002 Aug; 347(7):472-80. PubMed ID: 12181401
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [A case of metastatic gastrointestinal stromal tumor developing a resistance to STI571 (imatinib mesylate)].
    Miyake M; Takeda Y; Hasuike Y; Kashiwazaki M; Mishima H; Ikenaga M; Mano M; Takada Y; Hirota S; Tsujinaka T
    Gan To Kagaku Ryoho; 2004 Oct; 31(11):1791-4. PubMed ID: 15553717
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apoptotic and anti-angiogenic strategies in liver and gastrointestinal malignancies.
    Kountouras J; Zavos C; Chatzopoulos D
    J Surg Oncol; 2005 Jun; 90(4):249-59. PubMed ID: 15906369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential expression of matrix metalloproteinase (MMP)-2, MMP-9, and membrane type 1-MMP in hepatocellular and pancreatic adenocarcinoma: implications for tumor progression and clinical prognosis.
    Määttä M; Soini Y; Liakka A; Autio-Harmainen H
    Clin Cancer Res; 2000 Jul; 6(7):2726-34. PubMed ID: 10914717
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Hepatocellular carcinoma: molecular pathogenesis and novel targets for therapy].
    Marquardt JU; Galle PR; Teufel A
    Dtsch Med Wochenschr; 2012 Apr; 137(16):855-60. PubMed ID: 22495921
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of imatinib mesylate (Gleevec/Glivec) in gastrointestinal stromal tumors.
    de Jong FA; Verweij J
    Expert Rev Anticancer Ther; 2003 Dec; 3(6):757-66. PubMed ID: 14686698
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting dynamics of subclones of GI, liver and pancreatic cancers.
    Ziogas DE; Glantzounis G; Liakakos T; Roukos DH
    Expert Rev Gastroenterol Hepatol; 2016 Jul; 10(7):773-6. PubMed ID: 27143511
    [No Abstract]   [Full Text] [Related]  

  • 18. [At last, an effective therapy for non-differentiated GI sarcomas (gastro intestinal stromal tumor)].
    Des Guetz G; De Mestier P; Pierga JY
    J Chir (Paris); 2002 Oct; 139(5):268-73. PubMed ID: 12410126
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted agents for sarcoma: is individualized therapy possible in such a diverse tumor type?
    Riedel RF
    Semin Oncol; 2011 Oct; 38 Suppl 3():S30-42. PubMed ID: 22055970
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Response to imatinib mesylate of a gastrointestinal stromal tumor with very low expression of KIT.
    Bauer S; Corless CL; Heinrich MC; Dirsch O; Antoch G; Kanja J; Seeber S; Schütte J
    Cancer Chemother Pharmacol; 2003 Mar; 51(3):261-5. PubMed ID: 12655446
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.